

Day One			Day Two			Day Three		
Opening Address								
Plenary I: Origins of Mesothelioma			Plenary III: Surgery – Individualising Care Appropriately			Plenary V: Cutting Edge 2021		
Parallel Mini-Symposia 1: Pathology	Parallel Mini-Symposia 2: Clinical Trials	Parallel Mini-Symposia 3: Local and Intrapleural Therapies	Parallel Mini-Symposia 7: Immunotherapy and Checkpoint Blockade	Parallel Mini-Symposia 8: Peritoneal Mesothelioma	Parallel Mini-Symposia 9: Symptoms and Pleural Management	Parallel Mini-Symposia 13: Biology and Novel Targets	Parallel Mini-Symposia 14: Epidemiology and Asbestos Control	Parallel Mini-Symposia 15: Biomarkers and Genetics II
Parallel Mini-Symposia 4: Surgery	Parallel Mini-Symposia 5: Cell Therapies and Mesothelin Directed Therapies	Parallel Mini-Symposia 6: Nursing and Supportive Care	Parallel Mini-Symposia 10: Biomarkers and Genetics	Parallel Mini-Symposia 11: Management Decisions in Mesothelioma	Parallel Mini-Symposia 12: Imaging	Plenary VI: Towards Tomorrow		
Plenary II: Focus on the Patient			Plenary IV: Immunotherapy - Checkpoint Blockade and Beyond			Presidential Closing Address		